Virtu Financial LLC Invests $186,000 in Solid Biosciences Inc (NASDAQ:SLDB) Stock

Virtu Financial LLC purchased a new position in shares of Solid Biosciences Inc (NASDAQ:SLDB) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 20,242 shares of the company’s stock, valued at approximately $186,000. Virtu Financial LLC owned 0.06% of Solid Biosciences as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of SLDB. Flinton Capital Management LLC purchased a new stake in shares of Solid Biosciences in the 4th quarter valued at about $47,000. First Manhattan Co. raised its holdings in shares of Solid Biosciences by 100.0% during the 4th quarter. First Manhattan Co. now owns 2,000 shares of the company’s stock valued at $53,000 after buying an additional 1,000 shares in the last quarter. Great West Life Assurance Co. Can purchased a new position in shares of Solid Biosciences during the 4th quarter valued at about $83,000. Legal & General Group Plc raised its holdings in shares of Solid Biosciences by 47.8% during the 3rd quarter. Legal & General Group Plc now owns 1,825 shares of the company’s stock valued at $86,000 after buying an additional 590 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its holdings in shares of Solid Biosciences by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 4,160 shares of the company’s stock valued at $111,000 after buying an additional 3,249 shares in the last quarter. Institutional investors own 63.39% of the company’s stock.

Solid Biosciences stock traded down $0.16 during trading hours on Wednesday, reaching $5.93. The company had a trading volume of 269,722 shares, compared to its average volume of 853,888. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.99 and a quick ratio of 10.31. The stock has a market capitalization of $205.71 million, a P/E ratio of -2.64 and a beta of 1.68. Solid Biosciences Inc has a 12-month low of $5.23 and a 12-month high of $54.84.

Solid Biosciences (NASDAQ:SLDB) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.85) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.22). Sell-side analysts expect that Solid Biosciences Inc will post -2.63 earnings per share for the current fiscal year.

In related news, major shareholder Boxer Capital, Llc sold 450,000 shares of Solid Biosciences stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $9.88, for a total transaction of $4,446,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Juan Andrey Zarur sold 8,000 shares of Solid Biosciences stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $10.00, for a total value of $80,000.00. The disclosure for this sale can be found here. 31.20% of the stock is currently owned by company insiders.

A number of equities analysts recently weighed in on the company. Zacks Investment Research cut Solid Biosciences from a “hold” rating to a “sell” rating in a report on Saturday. Citigroup set a $6.00 price objective on Solid Biosciences and gave the company a “hold” rating in a report on Thursday, May 16th. Chardan Capital cut Solid Biosciences from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $15.00 to $7.50 in a report on Tuesday, May 14th. Goldman Sachs Group cut Solid Biosciences from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $5.00 to $4.00 in a report on Tuesday, May 14th. Finally, Credit Suisse Group cut Solid Biosciences from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $7.00 to $6.00 in a research note on Tuesday, May 14th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. Solid Biosciences presently has a consensus rating of “Hold” and a consensus price target of $19.82.

ILLEGAL ACTIVITY WARNING: This article was first posted by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://sundanceherald.com/2019/05/22/virtu-financial-llc-invests-186000-in-solid-biosciences-inc-sldb-stock.html.

Solid Biosciences Profile

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Featured Story: Why do companies issue convertible shares?

Institutional Ownership by Quarter for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply